Sadie Stern Sells 427 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCMGet Free Report) EVP Sadie Stern sold 427 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $49,126.35. Following the sale, the executive vice president now owns 75,877 shares in the company, valued at $8,729,648.85. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Sadie Stern also recently made the following trade(s):

  • On Monday, March 25th, Sadie Stern sold 4,137 shares of DexCom stock. The shares were sold at an average price of $140.00, for a total value of $579,180.00.

DexCom Stock Down 2.9 %

Shares of DXCM stock opened at $113.81 on Friday. The stock has a market cap of $45.26 billion, a P/E ratio of 73.43, a PEG ratio of 2.86 and a beta of 1.22. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00. The company’s fifty day simple moving average is $128.03 and its two-hundred day simple moving average is $125.80. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCMGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. Analysts predict that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Hedge Funds Weigh In On DexCom

Hedge funds have recently added to or reduced their stakes in the stock. DSM Capital Partners LLC bought a new position in DexCom in the 4th quarter worth about $28,000. Crewe Advisors LLC bought a new position in shares of DexCom during the first quarter valued at approximately $29,000. Valley National Advisers Inc. boosted its stake in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Riverview Trust Co bought a new position in shares of DexCom during the first quarter valued at approximately $32,000. Finally, MV Capital Management Inc. boosted its stake in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

DXCM has been the topic of a number of research reports. Raymond James raised their price target on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. Redburn Atlantic initiated coverage on DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target on the stock. Canaccord Genuity Group raised their price target on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Royal Bank of Canada initiated coverage on DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target on the stock. Finally, StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Monday. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus target price of $140.94.

Read Our Latest Stock Analysis on DexCom

About DexCom

(Get Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Read More

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.